PDL BioPharma Change in Assets/Liabilities 2010-2020 | PDLI

PDL BioPharma change in assets/liabilities from 2010 to 2020. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities

PDL BioPharma Change in Assets/Liabilities 2010-2020 | PDLI

PDL BioPharma change in assets/liabilities from 2010 to 2020. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$231B
Amgen (AMGN)$161.4B
Gilead Sciences (GILD)$139.9B
Vertex Pharmaceuticals (VRTX)$96.3B
Bristol Myers Squibb (BMY)$93.3B
CSL (CSLLY)$83.8B
GSK (GSK)$76.1B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$54.9B
Argenex SE (ARGX)$41.3B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$21.3B
Insmed (INSM)$21.2B
Biogen (BIIB)$19.5B
Incyte (INCY)$15.2B
Illumina (ILMN)$15B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14.2B
BioMarin Pharmaceutical (BMRN)$11.9B
Ascendis Pharma (ASND)$11.4B
QIAGEN (QGEN)$11.1B
Moderna (MRNA)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exelixis (EXEL)$10.1B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Halozyme Therapeutics (HALO)$7.5B